Armistice Capital, LLC recently disclosed that they own 6.1% of Zosano Pharma Corp. (NASDAQ:ZSAN) in a Schedule 13G disclosure that was filed with the SEC on Monday, October 17th. The investor owns 1,024,000 shares of the stock worth about $634,880. The reporting parties listed on the disclosure included Armistice Capital, LLC, Armistice Capital Master Fund Ltd and Steven Boyd. The filing is available through Edgar at this hyperlink.
Separately, Vivo Capital LLC acquired a new position in shares of Zosano Pharma Corp. during the first quarter worth about $227,000. 35.89% of the stock is currently owned by hedge funds and other institutional investors.
Zosano Pharma Corp. (NASDAQ:ZSAN) traded down 6.79% during mid-day trading on Monday, reaching $0.62. 28,995 shares of the company’s stock were exchanged. The company’s 50-day moving average is $0.78 and its 200 day moving average is $1.46. Zosano Pharma Corp. has a one year low of $0.60 and a one year high of $3.27. The firm’s market capitalization is $7.45 million.
Zosano Pharma Corp. (NASDAQ:ZSAN) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($0.54) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by $0.04. Equities analysts predict that Zosano Pharma Corp. will post ($2.39) earnings per share for the current fiscal year.
A number of analysts have weighed in on the stock. Ladenburg Thalmann lowered shares of Zosano Pharma Corp. from a “buy” rating to a “neutral” rating in a research note on Thursday, August 11th. Zacks Investment Research lowered shares of Zosano Pharma Corp. from a “hold” rating to a “sell” rating in a research note on Thursday, August 25th.
In related news, major shareholder Enterprise Associates 12 New sold 23,681 shares of the company’s stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $1.27, for a total value of $30,074.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Konstantinos Alataris acquired 127,389 shares of the stock in a transaction that occurred on Friday, August 19th. The stock was acquired at an average cost of $1.32 per share, with a total value of $168,153.48. The disclosure for this purchase can be found here. 5.37% of the stock is currently owned by corporate insiders.
Zosano Pharma Corp. Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Want to see what other hedge funds are holding ZSAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zosano Pharma Corp. (NASDAQ:ZSAN).
Receive News & Ratings for Zosano Pharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.